scholarly journals SAT0182 Sirukumab leads to significant and clinically meaningful improvements in health-related quality of life that meet or exceed normative values in patients with rheumatoid arthritis refractory to tnf inhibitors in post hoc analyses of a phase 3 trial

Author(s):  
V Strand ◽  
R Ganguly ◽  
N Li ◽  
K McQuarrie
Sign in / Sign up

Export Citation Format

Share Document